BiotechTube

Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mg

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Morbid Obesity

Conditions

Morbid Obesity

Trial Timeline

Nov 5, 2017 → Sep 1, 2018

NCT ID
NCT03246386

About Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mg

Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mg is a approved stage product being developed by Merck for Morbid Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT03246386. Target conditions include Morbid Obesity.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03246386ApprovedCompleted

Competing Products

7 competing products in Morbid Obesity

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaApproved
85
RocuroniumMerckApproved
85
Placebo + IBI362Innovent BiologicsPhase 3
76
Supemtek® + Vaxigriptetra®SanofiPhase 3
76
MolindoneSupernus PharmaceuticalsPhase 2
47
SPN-810MSupernus PharmaceuticalsPhase 1
28
SPN-810 + PlaceboSupernus PharmaceuticalsPhase 2
47

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85